Breaking News
March 23, 2018 - Wales participates in the 100,000 Genomes Project
March 23, 2018 - 24-Hr Paging Cuts ED Visits for Kids with Endocrine Issues
March 23, 2018 - The brain learns completely differently than we’ve assumed since the 20th century
March 23, 2018 - Less nutritious diet mainly contributes to Type 2 diabetes among U.S.-based South Asians
March 23, 2018 - Stony Brook Medicine expert provides tips for healthy diet to decrease cancer risk
March 23, 2018 - New findings could have revolutionary impact on quality of life of older people
March 23, 2018 - Restoring enzyme may help reverse effects of vascular aging, study shows
March 23, 2018 - Protein profiling reveals new prostate cancer mechanisms
March 23, 2018 - FDA Takes Aim at Flavored Tobacco
March 23, 2018 - SMART Strategy Lowers Asthma Exacerbation Risk
March 23, 2018 - Cold open water plunge provides instant pain relief
March 23, 2018 - Patients with vascular malformations have poor health-related quality of life
March 23, 2018 - New DOD grant to support testing of promising therapy for triple-negative breast cancer
March 23, 2018 - Novel vaccine technologies can help better prepare for future infectious disease threats
March 23, 2018 - OncoBreak: Colonoscopy TV; Coverage for Genomic Testing; Care for Caregivers
March 23, 2018 - For some surgeries, nerve blocks mean better outcomes, fewer opioids
March 23, 2018 - Maternal obesity and androgen excess induce sex-specific anxiety in offspring, study suggests
March 23, 2018 - The tale of Theranos and the mysterious fire alarm
March 23, 2018 - USC researchers create algorithm to optimize substance abuse intervention groups
March 23, 2018 - Impulsivity may be associated with greater weight loss during treatment in obese children
March 23, 2018 - CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
March 23, 2018 - Senate Panel Addresses Native Americans’ Opioid Troubles
March 23, 2018 - Brain connections in schizophrenia
March 23, 2018 - Mental health assessment in health checks can help detect psychologically vulnerable people
March 23, 2018 - New test for urothelial cancers offers less invasive, more accurate detection
March 23, 2018 - Groundbreaking 100,000 Genomes Project achieves important milestone to transform NHS care
March 23, 2018 - Mice getting a new lease of life with anti-aging pills
March 23, 2018 - Obesity kills taste buds and dulls taste sensation finds study
March 23, 2018 - Medical students get less formal education in radiation oncology, study finds
March 23, 2018 - Researchers find investigational compound to treat triple negative breast cancer after brain metastasis
March 23, 2018 - Researchers develop wearable system to monitor electrical activity in the stomach over 24 hours
March 23, 2018 - A Different Opioid Crisis | Medpage Today
March 23, 2018 - PTSD an ongoing fight for generation of Iraq War vets
March 23, 2018 - Researchers uncover specific gene region in hypertension
March 23, 2018 - Specific immune cells may help slow progression of ALS, research shows
March 23, 2018 - Biosense Webster launches new ‘Power to Heal’ campaign to alleviate AF burden
March 23, 2018 - FDA could curb or ban tobacco in menthol or fruit flavoured cigarettes soon
March 23, 2018 - Mom’s Pre-Pregnancy Waist Size Tied to Autism Risk
March 23, 2018 - AMD Treat-and-Extend Regimens OK: Ophthalmology Times
March 23, 2018 - Safe-sleep recommendations for infants have not reduced sudden deaths in newborns
March 23, 2018 - Survey finds inappropriate prescribing of antibiotics for hospitalized children
March 23, 2018 - Researchers propose alternative treatment to target lymphoma signaling at its root
March 22, 2018 - Compound found in beet extract could help slow progression of Alzheimer’s disease
March 22, 2018 - Lower temperatures can trigger the body’s ‘good’ fat formation at cellular level
March 22, 2018 - Sentinel lymph node biopsies could be safely avoided for some breast cancer patients
March 22, 2018 - Combined Preeclampsia Test Superior to U.K. Standards
March 22, 2018 - Exclusive breastfeeding in hospital associated with longer breastfeeding duration
March 22, 2018 - Researchers prove link between common childhood cancer and inflammation
March 22, 2018 - Targeting aberrantly active telomerase to treat therapy-resistant melanoma
March 22, 2018 - California’s tax on millionaires yields big benefits for people with mental illness, study finds
March 22, 2018 - Weight-loss surgery reduces risk for severe chronic kidney disease and kidney failure
March 22, 2018 - Study identifies two genes associated with extreme nausea and vomiting during pregnancy
March 22, 2018 - Biohaven Enrolls First Patient In Phase 3 Clinical Trial To Evaluate Rimegepant Zydis® ODT In The Acute Treatment Of Migraine
March 22, 2018 - ‘Bionic Pancreas’ OK for Very Young T1D Patients
March 22, 2018 - Parkinson’s gene initiates disease outside of the brain
March 22, 2018 - NMSU researchers publish findings on effective measures to remedy stress among adolescents
March 22, 2018 - Immunotherapy combination increases overall survival in people with kidney cancer, study shows
March 22, 2018 - Increased rate of accidental injuries associated with poorer hearing ability
March 22, 2018 - Gut microbiome may promote pancreatic cancer by inducing immune suppression
March 22, 2018 - New ocular inserts allow patient’s cornea to absorb more antibiotics
March 22, 2018 - FDA Alert: NeuroBlate Probe by Monteris Medical: Letter to Health Care Providers, Class I Recall
March 22, 2018 - Cessation of exercise can result in increased depressive symptoms
March 22, 2018 - Morning Break: Booze Study Brouhaha; Stem Cells for MS; Big Debt Problem
March 22, 2018 - New wearable tech from Western may hold big benefits for people with Parkinson’s
March 22, 2018 - Immune cells can repopulate in the retina after elimination, mice study shows
March 22, 2018 - States extend Medicaid for birth control, cutting costs — and future enrollment
March 22, 2018 - Research provides better understanding of how cancerous cells behave in low oxygen
March 22, 2018 - Menopausal hormone therapy taken soon after menopause may benefit the brain
March 22, 2018 - Booze Boosts Your Heart Rate
March 22, 2018 - Skeptical Cardiologist: Classifying Heart Failure
March 22, 2018 - Instead of nagging your spouse to lose weight, try going on a diet yourself
March 22, 2018 - Neem Biotech to share findings on cystic fibrosis biofilm disruption at ECFS Basic Science Conference
March 22, 2018 - Study uncovers new genetic cause of posterior polymorphous corneal dystrophy
March 22, 2018 - ENDO: Big Breakfast May Help in Diabetics
March 22, 2018 - I’m not overweight, so why do I need to eat healthy foods?
March 22, 2018 - UCLA-led study suggests unexpected reason for reduction in cardiovascular health disparities
March 22, 2018 - Study suggests detailed neuropsychological assessment for brief cardiac arrest survivors
March 22, 2018 - Anticoagulant drugs found safe to use in patients undergoing surgery for irregular heartbeat
March 22, 2018 - SP Industries appoints Brian Larkin as new President and CEO
March 22, 2018 - GTx Announced New Data Demonstrating Enobosarm’s Potential to Treat Stress Urinary Incontinence
Enzalutamide Safe In Seizure-Prone Prostate CA Patients

Enzalutamide Safe In Seizure-Prone Prostate CA Patients

image_pdfDownload PDFimage_print

Action Points

  • The androgen receptor inhibitor enzalutamide (Xtandi) did not raise seizure incidence when used at a dose of 160 mg/day in men with metastatic castration-resistant prostate cancer (mCRPC) at risk for seizures, in a multicenter, multinational trial.
  • Note that the data, along with the previously established efficacy profile, suggest that enzalutamide does not predispose to seizures and may be safely used in men with metastatic prostate cancer who have risk factors for seizure.

In men with metastatic castration-resistant prostate cancer (mCRPC) at risk for seizures, the androgen receptor inhibitor enzalutamide (Xtandi) didn’t raise seizure incidence when used at a dose of 160 mg/day, researchers found in a manufacturer-sponsored study.

Confirmed seizure incidence in the Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer Patients Treated With Enzalutamide (UPWARD) was 2.6 per 100 patient-years, according to Susan Slovin, MD, PhD, of Memorial Sloan Kettering Cancer Center in New York City, and colleagues.

That’s about the same as the incidence previously calculated in a large retrospective analysis in the U.S., at 2.8 per 100 patient-years in patients with mCRPC and seizure risk factors who never took the drug, Slovin and colleagues reported online in JAMA Oncology.

“These data suggest that enzalutamide did not increase seizure incidence in men with mCRPC and seizure risk factors and is an option for patients with seizure risk factors,” the researchers wrote. “However, it should be used with caution and input from neurology specialists.”

“The risk profile presented, along with the previously established efficacy profile, suggests that enzalutamide can benefit patients with seizure risk factors, who should be closely monitored throughout the duration of treatment to ensure continued benefit and safety,” they added.

Jim Hu, MD, MPH, of New York Presbyterian/Weill Cornell Medicine in New York City, who wasn’t involved in the study, noted that the results contrast to those of a prior study, but they do suggest that “enzalutamide does not predispose to seizure. This demonstrates that enzalutamide may be safely used in men with metastatic prostate cancer who have risk factors for seizure.”

UPWARD was initiated following requests for additional safety information from the FDA and the European Medicines Agency. Although enzalutamide is known to prolong survival in men with mCRPC, phase I and II studies reported seizures in 3 of 140 (2%) enzalutamide-treated patients at doses greater than 360 mg/day.

Controlled clinical trials such as AFFIRM, PREVAIL, TERRAIN, and STRIVE have shown that with 160 mg of oral enzalutamide daily, only 0.5% of patients experienced seizure. However, patients with a history of seizure or risk factors were excluded from these trials, the researchers noted.

For UPWARD, they evaluated 423 patients at 73 sites in 20 countries, all of whom had at least one risk factor for seizure, including medications that lowered seizure threshold (57.2%); history of brain injury (26.5%); and history of cerebrovascular accident or transient ischemic attack (22.2%).

All patients received oral enzalutamide at a dose of 160 mg/day for an initial 4-month treatment period, and were given the option to extend treatment for one year.

Overall, 4 out of 366 evaluable patients (1.1%) had at least one confirmed seizure within 4 months of starting enzalutamide. The seizures were considered enzalutamide-related in 3 of the 4 patients. In addition, 3 patients (0.8%) had a seizure in the 4-month period after the study ended.

All 423 patients were included in the safety analysis. The majority (84.4%) experienced at least one treatment-emergent adverse event: 33.3% had at least one serious treatment-emergent adverse event, and 6.9% had at least one drug-related serious adverse event.

A total of 66 patients (15.6%) permanently discontinued treatment as a result of a drug-related AE, and three of these patients had a seizure, the researchers reported.

During the 4-month study period or within 30 days of the treatment ending, there were 38 deaths (9%), four of which were considered possibly drug-related. One patient died of cerebral hemorrhage, one of mCRPC progression, one experienced sudden cardiac death, and another had general deterioration. No seizure-related deaths were reported.

Study limitations included the fact that a randomized controlled trial wasn’t feasible, and that predisposing risk factors for seizure such as a history of seizure or of brain arteriovenous malformations were underrepresented, the researchers said.

“The risk profile presented, along with the previously established efficacy profile, suggests that enzalutamide can benefit patients with seizure risk factors, who should be closely monitored throughout the duration of treatment to ensure continued benefit and safety,” they concluded.

This study was funded by Astellas Pharma and Medivation (acquired by Pfizer in September 2016), the co-developers of enzalutamide. Both sponsors participated in the design and conduct of the study as well as analysis and interpretation of the data, approval of the manuscript, and decision to submit for publication. Lead author Slovin reported a relationship with Bayer AG. A number of co-authors also reported relationships with industry, including Astellas Pharma, Medivation, and Pfizer.


Tagged with:

About author

Related Articles